1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Taiwan Advanced Nanotech, Inc.

Taiwan Advanced Nanotech, Inc.

TTPEX:6797
10.45
TWD
-0.55
(-5.00%)
417.42MMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.55
4.35
4.44
63.35
63.99
44
8.06
6.43
5.05
- -
Basic EPS, GAAP
-0.78
-0.89
-1.43
22.78
20.77
10.81
-6.83
-6.2
-7.41
- -
Free Cash Flow per Basic Share
-3.03
-0.46
-2.03
21.21
17.36
11.92
-12.13
-0.66
-0.77
- -
Dividend per Share
- -
- -
- -
- -
9.78
4.61
3
- -
- -
- -
Book Value per Share
3.89
6.08
4.87
31.35
42.32
48.55
38.83
32.78
25.69
22.54
Tangible Book Value per Share
3.83
6.01
4.82
31.3
42.15
48.39
38.72
32.74
25.68
22.53
Basic Weighted Avg Shares
17
23
26
27
30
30
30
31
31
30
Sales/Revenue/Turnover
62
102
114
1,719
1,928
1,327
246
198
154
- -
Operating Margin (%)
-22.91
-27.64
-37.13
46.35
41.4
25.94
-106.43
-104.9
-150.51
- -
Depreciation Expense
8
9
14
33
85
111
121
115
103
- -
Net Income, GAAP
-14
-21
-37
618
626
326
-208
-191
-227
- -
Effective Tax Rate (%)
- -
- -
- -
20.04
20.88
22.45
- -
- -
- -
- -
Profit Margin (%)
-22
-20.56
-32.12
35.96
32.46
24.58
-84.76
-96.45
-146.79
- -
Working Capital
85
144
106
740
941
1,191
918
813
641
557
LT Debt
6
1
28
283
329
288
193
177
141
123
Total Equity
118
184
147
948
1,275
1,512
1,193
1,007
772
663
Return on Invested Capital (%)
- -
- -
- -
77.25
37.26
13.35
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
82.18
40.83
16.04
- -
- -
- -
- -
Return on Common Equity (%)
- -
-13.89
-22.09
112.86
56.33
23.67
-15.57
-17.32
-25.46
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
217
267
163
LT Borrowings
- -
- -
- -
LT Finance Leases
160
141
123
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
31
30
29
Market Capitalization
481
469
417

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
995
955
767
Cash, Cash Equivalents & STI
730
764
639
Accounts Receivable, Net
14
17
21
Inventories
235
161
95
Total Current Liabilities
270
315
210
Payables & Accruals
- -
- -
- -
ST Debt
217
267
163
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-1.38%
-23.33%
Free Cash Flow
- -
-64.51%
15.26%
Net Income, GAAP
- -
-40.01%
18.91%
Sales/Revenue/Turnover
- -
-28.39%
-21.87%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
198
2025
- -
- -
154
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-6.2
2025
- -
- -
-7.41
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chien Hsing Chien
Full Time Employees
292
Sector
Health technology
Industry
Medical specialties
Address
No.95, Xinpu 6th Street Taoyuan TP Taiwan 330
IPO Date
Nov 5, 2020
Website
tanbead.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Taiwan Advanced Nanotech Inc. Taiwan Advanced Nanotech Inc. (TANBead) designs, manufactures, and markets nucleic acid purification products for molecular diagnostics and life sciences applications; core offerings include automated extraction instruments such as the Maelstrom series with patented magnetic bead stirring technology, reagent kits for DNA/RNA extraction from diverse samples, magnetic nanoparticles, qPCR-related molecular biology reagents, and GMP-compliant consumables. The company, founded in 2004 and headquartered in Taoyuan City, Taiwan, operates a QMS-certified manufacturing facility with ISO 13485 compliance and clean room production, exporting to over 80 countries while holding core patents in the United States, European Union, Canada, Japan, South Korea, China, and Taiwan. Products support in vitro diagnostic use with FDA and CE approvals, targeting clinical labs, research institutions, and biotech firms globally; as a publicly listed entity since 2020 (ticker: 6797.TWO), it received the Excellence in Innovation Technology award at the 2023 Taipei Biotech Awards and Silver Prize at the 2023 National Medicine Research and Development Awards, alongside launching new molecular biology reagents and advanced kits like the 66P Universal Pathogen Kit for complex samples.